Thyroid Cancer in Women in India: Signs, Tests & Outlook

• Most neck lumps are not cancer — around 90–95% of thyroid nodules turn out to be benign on testing.
• Women are affected roughly 3 times more than men, partly due to hormonal influences and more frequent thyroid scanning.
• The standard pathway is neck ultrasound, then a fine-needle test (FNAC) reported on the 6-category Bethesda scale.
• The outlook is excellent: papillary thyroid cancer (the commonest type) has 10-year survival near 99% when caught early.
• Treatment is becoming more conservative — active surveillance or removing just one lobe is now an option for many small, low-risk cancers.
• See a doctor promptly for any new or growing neck lump, especially with a hoarse voice, swallowing trouble, or swollen neck glands.

Thyroid cancer is now among the more common cancers in Indian women, and its incidence has been climbing roughly 4–5% a year over the past decade in Indian cancer registries — mirroring a worldwide trend.

The most striking feature is how lopsided it is by sex. The female-to-male ratio is about 3:1, both globally and in Indian data, making thyroid cancer one of the most female-predominant cancers there is.

The reasons are only partly understood. Hormonal influences clearly matter — incidence rises during the reproductive years and eases somewhat after menopause, and thyroid tissue carries estrogen and progesterone receptors. Women also have proportionally larger thyroids and far more thyroid disease in general (Hashimoto's, Graves', and multinodular goitre), which means more neck scans and more chance of spotting a small cancer by accident. Some of the rise is genuinely more cancer; some is simply better detection.

The stage at which thyroid cancer shows up in India is usually favourable. Because a neck lump or a voice change is noticeable, most women come for evaluation early — around 70–80% of the common (differentiated) thyroid cancers are caught at an early stage.

A few things raise risk: radiation exposure in childhood (a single dental X-ray is negligible, but substantial cumulative radiation is not), borderline iodine status (India has largely controlled severe deficiency through salt iodisation, but pockets remain — see iodine deficiency in pregnancy in India), a family history of thyroid cancer, and longstanding Hashimoto's thyroiditis. For most women, though, no clear cause is ever found.

The classic sign is a painless lump low in the front-centre of the neck, where the thyroid sits — just below the Adam's apple and above the notch at the top of the breastbone. Thyroid nodules are extremely common (felt in 5–10% of adults, seen on ultrasound in 30–50%), and around 90–95% are benign. The job is to pick out the small minority that need attention.

Features that should prompt prompt evaluation include:

Most non-cancerous thyroid lumps are colloid nodules (semi-fluid collections), simple cysts, benign tumours called follicular adenomas, the lumpy texture of Hashimoto's, or a multinodular goitre from long-term thyroid stimulation. These tend to grow slowly or stay stable and don't cause hoarseness, swallowing trouble, or swollen neck glands unless very large.

No single sign settles it — it's the combination that matters. A small, soft, mobile nodule in a 40-year-old woman with normal thyroid blood tests and no family history is reassuring. A hard, fixed, growing lump with a hoarse voice and swollen neck glands needs urgent assessment, whatever the age.

A simple neck self-check is reasonable, though it isn't a formal screening test. Stand at a mirror, tip your head back slightly, take a sip of water and swallow, and watch the lower neck — anything that bulges or rises with the swallow may be the thyroid. The normal gland usually isn't felt as a distinct lump, so if you notice something new, see a doctor rather than diagnosing yourself from image searches online. A new lump is not a reason to start thyroid tablets on your own — it's a reason to be examined and scanned. (Note: a swollen gland elsewhere, such as the Swollen Lymph Nodes in the Groin: Causes and When to Worry, has different causes entirely.)

When a nodule is suspected, the first test is a thyroid ultrasound — painless, radiation-free, and able to show a nodule's size, number, and texture. Radiologists grade nodules using a system called TIRADS, which scores features such as whether a nodule is solid or cystic, dark or bright on the scan, taller than it is wide, irregularly edged, or speckled with tiny calcifications. Scores run from TR1 (benign, no further test) to TR5 (highly suspicious, sample it).

Blood tests for thyroid function (TSH, free T4, sometimes antibodies) are usually done alongside. In most women with a nodule the thyroid is working completely normally, because most cancers don't change hormone output. A raised TSH may point to Hashimoto's; a low TSH may mean a "hot," overactive nodule, which is rarely cancerous. Our overview of thyroid symptoms in women explains what these numbers mean.

If the nodule looks suspicious or is over about 1 cm, the key test is fine-needle aspiration cytology (FNAC). A thin needle, guided by ultrasound, draws a few cells from the nodule under local anaesthetic. It's an outpatient procedure taking 15–30 minutes, with minimal discomfort, and usually costs around ₹1,500–4,000 privately (free or nominal at government centres).

Results are reported on the Bethesda system — six categories, each with a known cancer risk and a clear next step:

About 90–95% of thyroid cancers are "differentiated" — papillary or follicular — and these are the highly treatable ones.

Papillary thyroid cancer is by far the most common (around 80% of all cases). It usually appears in women aged 30–50, grows slowly, and may spread first to neck lymph nodes (which, unusually, is not a sign of a poor outcome here). Early-stage papillary cancer has 10-year survival approaching 99%.

Follicular thyroid cancer (about 10–15%) tends to appear a little later in life and spreads through the bloodstream rather than the lymph nodes; its outlook is slightly less favourable but still excellent for early disease (10-year survival of 85–95%). Both papillary and follicular cancers usually respond to radioactive iodine and to TSH-suppressing levothyroxine.

Medullary thyroid cancer (3–5%) arises from different cells and behaves differently — it doesn't take up iodine, so radioactive iodine doesn't work, and treatment is mainly surgical. Around a fifth of cases are inherited as part of a syndrome called MEN2, so everyone with medullary cancer should have RET gene testing.

Anaplastic thyroid cancer is rare (under 1–2%) but aggressive, usually in older patients, and is the one clear exception to the otherwise excellent outlook. For perspective on how thyroid cancer compares with other women's cancers, see our guides to ovarian cancer symptoms and endometrial (uterine) cancer.

Treatment has shifted notably over the past decade toward doing less, not more. There is growing recognition that very small, low-risk papillary cancers (under 1 cm, no node involvement, no worrying features) may not need immediate surgery at all. Long-running Japanese studies of "active surveillance" — careful watching with regular scans — found that only about 8–15% of these tiny cancers progress over 10 years, and all of those were treated successfully when they did. Indian centres are adopting this cautiously for carefully chosen patients.

For most cancers, though, surgery remains the main treatment, and the choice is between:

If neck lymph nodes are involved, the surgeon removes the affected compartments as part of the operation. Modern thyroid surgery focuses on protecting two delicate structures: the nerves to the voice box (recurrent laryngeal nerves) and the tiny parathyroid glands that control your calcium. High-volume centres increasingly use intraoperative nerve monitoring to safeguard the voice nerves.

Done at experienced, high-volume centres (such as Tata Memorial, AIIMS, RGCI, Apollo, Manipal, HCG, or Narayana), complication rates are low: temporary hoarseness in 2–5%, permanent hoarseness under 1–2%, and temporary low-calcium symptoms in 5–15%. Choosing a surgeon and centre that do many thyroid operations matters more than almost any other factor.

Indicative 2026 costs at major Indian centres:

After a total thyroidectomy, selected patients are given radioactive iodine (I-131) to mop up any remaining thyroid tissue. It works because thyroid cells — normal and cancerous — uniquely absorb iodine, so the radiation is delivered precisely where it's needed. It's given 4–8 weeks after surgery and is widely available at Indian hospitals with nuclear medicine units. Treatment usually means a 1–3 day stay in a shielded room, followed by 1–2 weeks of limiting close contact with others (especially children and pregnant women). Costs run roughly ₹25,000–1.5 lakh, and it is covered under PMJAY at empanelled hospitals.

Who needs it has become more selective: many low-risk patients now skip it entirely, while higher-risk patients receive larger doses. The decision is individualised using a recognised risk-classification system.

After surgery (and iodine if given), almost everyone takes a daily levothyroxine tablet for life. Beyond replacing the hormone, the dose is often set to gently suppress TSH and reduce any stimulation of leftover cancer cells. Follow-up combines periodic neck ultrasound, TSH/free T4 blood tests, and a tumour marker called thyroglobulin — a rising level can be an early signal of recurrence.

Levothyroxine replacement is straightforward, but a few habits make it work well. Indian brands (Thyronorm, Eltroxin, Thyrox and others) are affordable — around ₹100–400 a month — and effective. Because brands can differ slightly in absorption, it's best to stay on one brand once your dose is settled.

Take it on an empty stomach 30–60 minutes before breakfast with water only (or at bedtime, 3–4 hours after eating). Keep it 4 hours apart from coffee, tea, calcium or iron supplements, antacids, soy and fibre, all of which blunt absorption — worth keeping in mind if you also take calcium supplements. Have your TSH checked 6–8 weeks after any dose change, then every 6–12 months once stable.

One caution: over-suppressing TSH for years can, in some women, raise the risk of an irregular heartbeat and bone thinning — so the degree of suppression should be reviewed periodically and eased once it's no longer needed, especially after menopause.

Finally, an excellent prognosis doesn't make the experience trivial. Many survivors deal with lingering fatigue, weight changes, a neck scar, voice fatigue, and a very real fear of recurrence. That deserves acknowledgement and support — peer survivor networks at major cancer centres, online thyroid-cancer communities, and hospital counselling all help. Adjusting to lifelong medication and ongoing checks takes time, and that's normal.

Thyroid cancer in pregnancy is uncommon, and the news is largely reassuring. Most differentiated cancers grow slowly enough that surgery can usually wait — until the second trimester, when surgery is safest, or even until after delivery for many low-risk cases.

The workup uses pregnancy-safe tests: ultrasound is the mainstay, FNAC is safe, and blood tests are standard. CT scans and radioactive iodine are avoided in pregnancy and while breastfeeding.

Women already on levothyroxine for past thyroid cancer need closer monitoring once pregnant — requirements typically rise by 20–30% by the second trimester, and TSH should be kept within pregnancy-specific targets (usually below 2.5 mIU/L early on). Our detailed guide to thyroid TSH targets by trimester covers this, and thyroid and fertility explains conception planning.

Fertility after treatment is generally well preserved. After radioactive iodine, current guidance is to wait 6–12 months before trying to conceive, allowing the ovaries to recover and disease status to settle. If a more intensive cancer treatment is ever anticipated, see fertility preservation for cancer survivors.

Most thyroid cancers are sporadic, with no inherited cause. But a handful of genetic syndromes raise the risk and justify genetic evaluation.

The most important is MEN2, caused by RET gene mutations: nearly everyone with MEN2 develops medullary thyroid cancer, often young, alongside risks to the adrenal and parathyroid glands. Everyone with medullary cancer should have RET testing, and relatives of a confirmed carrier should be offered cascade testing. For carriers, removing the thyroid preventively — at an age set by the specific mutation — can stop the cancer before it starts, one of medicine's clearest examples of prevention through genetics.

Other syndromes (Cowden, familial adenomatous polyposis and others) carry smaller thyroid risks alongside breast, uterine or bowel risks. Families with several relatives affected without an identified gene still warrant surveillance of close relatives.

Genetic counselling is available at major Indian cancer centres and private labs. Indicative costs: RET testing ₹15,000–30,000; a multi-gene hereditary cancer panel ₹25,000–50,000; cascade testing for a known family mutation ₹5,000–10,000. If you're weighing inherited cancer risk more broadly, our guides to genetic carrier screening and BRCA testing cost in India are useful background. For most women with sporadic cancer and no family history, gene testing isn't needed.

Part of the global rise in thyroid cancer comes from finding tiny, harmless cancers that would never have caused trouble — a problem called over-diagnosis. South Korea is the cautionary tale: after widespread ultrasound screening began, thyroid cancer diagnoses rose 15-fold, yet deaths from it didn't change at all. Almost all the extra cancers were small and indolent.

The response has been to right-size treatment. Active surveillance is now accepted for carefully selected papillary microcarcinomas (under 1 cm), and radioactive iodine is used more sparingly. The choice between watching and operating is genuinely nuanced — it depends on your anxiety about an untreated cancer, your ability to commit to regular follow-up, surgical risk, and personal values. Many Indian patients prefer the certainty of treatment, and that is an equally valid choice.

The practical message is balanced: not every nodule needs an FNAC, and not every cancer needs maximum treatment — but you should still get a new lump properly evaluated. Don't skip assessment for fear of being overtreated; do have an informed conversation about your options once a diagnosis is confirmed.

See a doctor promptly — within days, not months — if you notice any of the following. Most will turn out to be harmless, but they all deserve a proper examination and, usually, an ultrasound.

• American Thyroid Association — 2015 Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
• ICMR National Cancer Registry Programme (NCRP), National Centre for Disease Informatics and Research
• World Health Organization — Cancer fact sheets
• National Cancer Institute (US) — Thyroid Cancer Treatment (PDQ)
• NHS — Thyroid cancer
• American Cancer Society — Thyroid Cancer